SLNO Soleno Therapeutics Inc

Soleno Therapeutics to Participate in Upcoming November Conferences

Soleno Therapeutics to Participate in Upcoming November Conferences

REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November:

Guggenheim Securities Healthcare Innovation Conference

Presentation Date: Tuesday, November 11, 2025 at 9:00 AM ET

Presentation Format: Fireside Chat

Webcast:

Stifel 2025 Healthcare Conference

Presentation Date: Wednesday, November 12, 2025 at 8:40 AM ET

Presentation Format: Fireside Chat

Webcast:

Jefferies London Healthcare Conference

Presentation Date: Tuesday, November 18, 2025 at 5:00 PM GMT

Presentation Format: Presentation

Webcast:

Replays of the events will be available in the Investors section on the Company’s website at .

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKAT XR™ (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit .

Corporate Contact:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578



EN
28/10/2025

Underlying

SLNOSoleno Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Soleno Therapeutics Inc

 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics to Participate in Upcoming November Conferences

Soleno Therapeutics to Participate in Upcoming November Conferences REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November: Guggenheim Securities Healthcare Innovation ConferencePresentation Date: Tuesday, November 11, 2025 at 9:00 AM ETPresentation Format: Fireside ChatWebcast: Stifel 2025 Healthcare ConferencePresentation Date: Wednesday, November 1...

October 28, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics to Report Third Quarter 2025 Financial Results on ...

Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results an...

October 21, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn ...

Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors Appointment adds three decades of financial and operational leadership to Soleno’s Board REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board n...

October 13, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics to Participate in Upcoming September Conferences

Soleno Therapeutics to Participate in Upcoming September Conferences REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September: Cantor Global Healthcare ConferencePresentation Date: Wednesday, September 3, 2025 at 1:00 PM ETPresentation Format: Fireside ChatWebcast: Wells Fargo Healthcare ConferencePresentation Date: Thursday, September 4, 2025 at 1:30 ...

August 27, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and...

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2...

August 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch